Nextgen Biomed Ltd

Symbol: NXGN.TA

TLV

101.8

ILA

Market price today

  • -106.3909

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 7.56M

    MRK Cap

  • 0.00%

    DIV Yield

Nextgen Biomed Ltd (NXGN-TA) Stock Price & Analysis

Shares Outstanding

7.43M

Gross Profit Margin

0.00%

Operating Profit Margin

0.00%

Net Profit Margin

0.00%

Return on Assets

-0.54%

Return on Equity

-0.61%

Return on Capital Employed

-0.16%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO:Mr. Harel Hershtik
Full-time employees:15
City:Tel Aviv
Address:132 Azrieli Towers Round Building
IPO:2002-08-12
CIK:

Nextgen Biomed Ltd develops topical treatment for psoriasis. The company was formerly known as Sela Group.Com Ltd. and changed its name to Nextgen Biomed Ltd in February 2010. Nextgen Biomed Ltd was incorporated in 1990 and is based in Tel Aviv, Israel.

General Outlook

In simple terms, Nextgen Biomed Ltd has 7.431 M shares that people are buying and selling right now.

Return on Investments

The company's asset efficiency, represented by a robust -0.539% return, is a testament to Nextgen Biomed Ltd's adeptness in optimizing resource deployment. Nextgen Biomed Ltd's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.611%. Furthermore, the proficiency of Nextgen Biomed Ltd in capital utilization is underscored by a remarkable -0.162% return on capital employed.

Stock Prices

Nextgen Biomed Ltd's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $148.8, while its low point bottomed out at $119. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Nextgen Biomed Ltd's stock market.

Liquidity Ratios

Analyzing NXGN.TA liquidity ratios reveals its financial health of the firm. The current ratio of 201.67% gauges short-term asset coverage for liabilities. The quick ratio (177.50%) assesses immediate liquidity, while the cash ratio (176.36%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio201.67%
Quick Ratio177.50%
Cash Ratio176.36%

Profitability Ratios

The effective tax rate stands at 0.03%, revealing its tax efficiency. The net income per EBT, 99.97%, and the EBT per EBIT, 370.18%, provide insights into its earnings hierarchy.

cards.indicatorcards.value
Effective Tax Rate0.03%
Net Income per EBT99.97%
EBT per EBIT370.18%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.02, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding178
Days of Payables Outstanding7227
Payables Turnover0.05

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.20, and free cash flow per share, -0.20, depict cash generation on a per-share basis. The cash per share value, 0.32, showcases liquidity position.

cards.indicatorcards.value
Operating Cash Flow per Share-0.20
Free Cash Flow per Share-0.20
Cash per Share0.32
Free Cash Flow to Operating Cash Flow Ratio1.00

Per Share Data

Net income per share, -0.20, reflects the portion of profit attributed to each share. The book value per share, 0.29, represents the net asset value distributed per share, while the tangible book value per share, 0.28, excludes intangible assets.

cards.indicatorcards.value
Net Income Per Share-0.20
Book Value Per Share0.29
Tangible Book Value Per Share0.28
Shareholders Equity Per Share0.29

Growth Ratios

EBIT growth, -228.62%, and operating income growth, -228.62%, offer insights into operational profitability progression. The net income growth, -236.16%, showcases bottom-line expansion, and the EPS growth, -211.04%, measures the growth in earnings per share.

cards.indicatorcards.value
EBIT Growth-228.62%
Operating Income Growth-228.62%
Net Income Growth-236.16%
EPS Growth-211.04%
EPS Diluted Growth-211.04%
Weighted Average Shares Growth9.26%
Weighted Average Shares Diluted Growth9.26%
Operating Cash Flow Growth-3.57%
Free Cash Flow Growth12.82%
10-Year Operating CF Growth per Share87.08%
5-Year Operating CF Growth per Share-10.86%
3-Year Operating CF Growth per Share-60.68%
10-Year Net Income Growth per Share94.10%
5-Year Net Income Growth per Share-282.49%
3-Year Net Income Growth per Share-372.28%
5-Year Shareholders Equity Growth per Share120.53%
3-Year Shareholders Equity Growth per Share550.50%
Asset Growth-36.99%
Book Value per Share Growth-45.63%
R&D Expense Growth29.63%
SGA Expenses Growth-18.02%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 166,680,377.062, captures the company's total value, considering both debt and equity. Income quality, 0.32, assesses the reliability of reported earnings.

cards.indicatorcards.value
Enterprise Value166,680,377.062
Income Quality0.32
Intangibles to Total Assets10.42%
Graham Number1.13
Return on Tangible Assets-64.28%
Graham Net Net0.06
Working Capital3,993,000
Tangible Asset Value10,698,000
Net Current Asset Value2,614,000
Average Payables154,000
ROIC-82.45%
ROE-0.69%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 71.61, and the price to book ratio, 71.61, reflect the market's valuation relative to the company's book value. Ratios like price to free cash flows, -5.23, and price to operating cash flows, -508.28, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio71.61
Price to Book Ratio71.61
Price Cash Flow Ratio-508.28
Enterprise Value Multiple-5.31
Price Fair Value71.61
Price to Operating Cash Flow Ratio-508.28
Price to Free Cash Flows Ratio-5.23
Price to Tangible Book Ratio13.91
Enterprise Value Over EBITDA-19.59
EV to Operating Cash Flow-60.54
Earnings Yield-4.99%
Free Cash Flow Yield-1.60%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Nextgen Biomed Ltd (NXGN.TA) on the TLV in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -106.391 in 2024.

What is the ticker symbol of Nextgen Biomed Ltd stock?

The ticker symbol of Nextgen Biomed Ltd stock is NXGN.TA.

What is company IPO date?

IPO date of Nextgen Biomed Ltd is 2002-08-12.

What is company current share price?

Current share price is 101.800 ILA.

What is stock market cap today?

The market cap of stock today is 7564330.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 15.